ArticleScientific reports2016
Reversible cardiac hypertrophy induced by PEG-coated gold nanoparticles in mice.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Nanoparticle-Based Therapies for Myocardial Injury and Heart Failure: A Systematic Review and Translational Appraisal of Preclinical Evidence.Biomolecules · 2026Pooled it
- Multifunctional biomaterial platforms for blocking the fibrosis process and promoting cellular restoring effects in myocardial fibrosis therapy.Frontiers in bioengineering and biotechnology · 2022Pooled it
- An overview of recent flexible- and soft-biomaterial applications in myocardial infarction and other cardiovascular diseases.Materials today. Bio · 2026Review
- Cardiotoxicity Challenges in Nanomaterial: Risk Assessment, Mechanisms, and Mitigation Strategies.International journal of nanomedicine · 2026Review
- Nanomedicine for Diagnosis and Treatment of Cardiac Fibrosis.International journal of nanomedicine · 2025Review
- Use of nanotechnology-based nanomaterial as a substitute for antibiotics in monogastric animals.Heliyon · 2024Review
- Gold Nanoparticles (AuNPs)-Toxicity, Safety and Green Synthesis: A Critical Review.International journal of molecular sciences · 2024Review
- Modification of Some Structural and Functional Parameters of Living Culture ofMaterials (Basel, Switzerland) · 2023Article
- Surface enhanced deep Raman detection of cancer tumour through 71 mm of heterogeneous tissue.Nanotheranostics · 2022Article
- Nanoparticle-Mediated Angiotensin-(1-9) Drug Delivery for the Treatment of Cardiac Hypertrophy.Pharmaceutics · 2021Article
- Nanoparticle delivery system, highly active antiretroviral therapy, and testicular morphology: The role of stereology.Pharmacology research & perspectives · 2021Review
- Nanoparticles: Promising Tools for the Treatment and Prevention of Myocardial Infarction.International journal of nanomedicine · 2021Review
- Nano-Neurotheranostics: Impact of Nanoparticles on Neural Dysfunctions and Strategies to Reduce Toxicity for Improved Efficacy.Frontiers in pharmacology · 2021Review
- Understanding Nanoparticle Toxicity to Direct a Safe-by-Design Approach in Cancer Nanomedicine.Nanomaterials (Basel, Switzerland) · 2020Review
- Role of gold nanoparticles in advanced biomedical applications.Nanoscale advances · 2020Review
- Nanoparticle delivery of cardioprotective therapies.Conditioning medicine · 2020Article
- Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases.International journal of nanomedicine · 2020Review
- Accumulation of gold nano-rods in the failing heart of transgenic mice with the cardiac-specific expression of TNF-α.Heart and vessels · 2019Article
- Size dependent effects of Gold Nanoparticles in ISO-induced Hyperthyroid Rats.Scientific reports · 2018Article
- Conjugating Existing Clinical Drugs With Gold Nanoparticles for Better Treatment of Heart Diseases.Frontiers in physiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gold nanoparticles (GNPs) are attracting more and more attention for their great potential value in biomedical application. Currently, no study has been reported on the chronic cardiac toxicity of GNPs after repeated administration. Here we carried out a comprehensive evaluation of the chronic cardiac toxicity of GNPs to the heart. Polyethylene glycol (PEG) -coated GNPs at three different sizes (10, 30 and 50 nm) or PBS was administrated to mice via tail vein for 14 consecutive days. Then the mice were euthanized at 2 weeks, 4 weeks or 12 weeks after the first injection. The accumulation of GNPs in the mouse heart and their effects on cardiac function, structure, fibrosis and inflammation were analysized. GNPs with smaller size showed higher accumulation and faster elimination. None of the three sizes of GNPs affected cardiac systolic function. The LVIDd (left ventricular end-diastolicinner-dimension), LVMass (left ventricular mass) and HW/BW (heart weight/body weight) were significantly increased in the mice receiving 10 nm PEG-GNPs for 2 weeks, but not for 4 weeks or 12 weeks. These results indicated that the accumulation of small size GNPs can induce reversible cardiac hypertrophy. Our results provide the basis for the further biomedical applications of GNPs in cardiac diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.